Advertisement

European Archives of Oto-Rhino-Laryngology

, Volume 276, Issue 5, pp 1321–1325 | Cite as

Association between occurrence of ossicular chain defect and osteoprotegerin gene expression in patients with chronic otitis media

  • Serhan Keskin
  • Arzu TatlıpınarEmail author
  • Pınar Ata
  • Selami Uzun
  • Mustafa Emrah Kınal
  • Burçin Erkal
Otology
  • 36 Downloads

Abstract

Objective

Chronic otitis media (COM) is an important debilitating public problem causing hearing loss due to irreversible resorption of the ossicular chain. Activation of osteoprotegerin (OPG) during an acute attack of COM prevents bone resorption.The aim of the study was to investigate the role of OPG gene expression level on ossicular chain resorption in chronic otitis media.

Materials and methods

Fifty operated COM patients were included in the study. While 20 patients underwent ossiculoplasty, 30 patients underwent type 1 tympanoplasty. For RNA isolation and OPG gene expression analysis, middle ear swabs were taken from nasopharynx in the ostium of the Eustachian tube. RNA was isolated with mRNA easy kit and kept at − 85 °C till the cDNA and expression analysis. Expression levels were analyzed with real-time quantitative PCR in comparison with PDGB gene expression level as an internal control.

Results

Sample Cq measurements of type 1 tympanoplasty group were higher than Cq measurements of the internal control group (p = 0.027; p < 0.05). In contrast, there was no statistically significant difference between sample Cq measurements of ossiculoplasty group and Cq measurements of the internal control group (p = 0.293; p > 0.05).

Conclusion

Since OPG gene expression level was significantly higher in type 1 tympanoplasty group, OPG gene regulation system may have an effect on ossicular chain destruction in COM.

Keywords

Tympanoplasty Ossiculoplasty Osteoprotegerin Gene expression 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Akyıldız AN (1998) Kronik Otitis Media (Chronic Otitis Media). In: Kulak Hastaliklari ve Mikrocerrahisi (Ear Disorders and Microsurgery). Bilimsel Tıp Yayınevi, Ankara, pp 337–354Google Scholar
  2. 2.
    Brendan F, Boyce MD, Xing L (2008) Functions of RANKL/RANK/OPG in bone modelling and remodelling. Arch Biochem Biophys 473:139–146CrossRefGoogle Scholar
  3. 3.
    Kurban S, Mehmedoğlu İ (2007) Osteoprotegerin, rank ve rank ligandı. Türk Biyokimya Dergisi 32(4):178–184Google Scholar
  4. 4.
    Yazıcı H, Uzunkulaoğlu H, Emir HK, Kızılkaya Z, Doğan S, Samim E (2010) Comparison of incus interpositioning technique versus glass ionomer cement application in type 2 tympanoplasty. Eur Arch Otorhinolaryngol 270:1593–1596Google Scholar
  5. 5.
    Bulgurcu S, Dikilitas B, Cukurova İ (2017) Comparison of hydroxyapatite prosthesis and incus interposition in incus defects. Turk Arch Otorhinolaryngol 55:69–71CrossRefGoogle Scholar
  6. 6.
    Chole RA (1993) Chronic otitis media, mastoiditis, and petrositis. In: Cummings CW (ed) Otolaryngology, head and neck surgery. St. Louis, Missouri, pp 2823–2839Google Scholar
  7. 7.
    Kurihara A, Toshima M, Yuasa R, Takasaka T (1991) Bone destruction mechanism in chronic otitis media with cholesteatoma:specific production by cholesteatoma tissue in culture of bone resorbing activity attributable to interleukin-1 alpha. Ann Otol Rhinol Laryngol 100:989–998CrossRefGoogle Scholar
  8. 8.
    Khosla S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology 142:5050–5055CrossRefGoogle Scholar
  9. 9.
    Hofbauer LC, Neubauer A, Heufelder AE (2001)Receptor activator of nuclear factor-kappa B ligand and osteoprotegerin:potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 92: 460–470CrossRefGoogle Scholar
  10. 10.
    Zehnder AF, Kristiansen AG, Adams JC, Kujawa SG, Merchant SN, McKenna MJ (2006) Osteoprotegrin knockout mice demonstrate abnormal remodeling of the otic capsule and progressive hearing loss. The Laryngoscope 116:201–206CrossRefGoogle Scholar
  11. 11.
    Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, Mumm S (2002) Osteoprotegerin deficiency and juvenile Paget’s disease.N. Engl J Med 347:175–184CrossRefGoogle Scholar
  12. 12.
    Zupan J, Komadina R, Marc J (2012) The relationship between osteoclastogenic andanti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues. J Biomed Sci 19:28CrossRefGoogle Scholar
  13. 13.
    Koizumi H, Suzuki H, Ikezaki S, Ohbuchi T, Hashida K, Sakai A (2015) Osteoclasts are not activated in middle ear cholesteatoma. J Bone Miner Metab  https://doi.org/10.1007/s00774-015-0655-5 Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Serhan Keskin
    • 1
  • Arzu Tatlıpınar
    • 1
    Email author
  • Pınar Ata
    • 2
  • Selami Uzun
    • 1
  • Mustafa Emrah Kınal
    • 1
  • Burçin Erkal
    • 2
  1. 1.Ear Nose and Throat ClinicHealth Science University Fatih Sultan Mehmet Health Practice and Research CenterIstanbulTurkey
  2. 2.Department of Medical GeneticMarmara University School of MedicineIstanbulTurkey

Personalised recommendations